Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chenodiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 known ✓ | Q96RI1 | 7/20 | 0.98 |
| ▸ | GPBAR1 | Q8TDU6 | 14/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.98 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.98 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ursodiol SCHEMBL8829737 | 1.00 | GPBAR1 (0.98) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Ursodiol SCHEMBL2547966 | 1.00 | GPBAR1 (0.98) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23704676 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22108119 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL22384718 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24199134 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337643 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL24061005 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL23517166 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A | |
| Chenodiol SCHEMBL25337648 | 0.99 | GPBAR1 (1.00) | GPBAR1NR1H4ABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 446 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102479-A1 | METHOD FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES | BIOLOGICAL E LTD (IN) | 2026-04-16 | — | — | US | claimed |
| EP-4590724-A1 | METHOD FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES | Biological E Limited (IN) | 2025-07-30 | — | — | EP | claimed |
| WO-2024062494-A1 | METHOD FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES | BIOLOGICAL E LIMITED (IN) | 2024-03-28 | — | — | WO | claimed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | claimed |
| CN-114948885-B | Improved abirater acetate Long Nami crystal oral preparation and preparation method thereof | 广东西捷药业有限公司 | 2023-11-28 | — | — | CN | claimed |
| EP-3740067-A1 | PERFUSION LOOP ASSEMBLY FOR AN EX-VIVO LIVER PERFUSION AND A METHOD FOR EX-VIVO LIVER PERFUSION | ETH Zürich (CH) | 2020-11-25 | — | — | EP | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| WO-2019141809-A1 | PERFUSION LOOP ASSEMBLY FOR AN EX-VIVO LIVER PERFUSION AND A METHOD FOR EX-VIVO LIVER PERFUSION | ETH Zürich (CH) | 2019-07-25 | — | — | WO | claimed |
| WO-2018204669-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2018-11-08 | — | — | WO | claimed |
| CN-106883281-B | The method that chenodeoxycholic acid is extracted from duck bile | 眉山市新功生物科技有限公司 | 2017-12-22 | — | — | CN | claimed |
| WO-2010036938-A2 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME | NANOBIO CORPORATION (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2010-03-25 | — | — | US | claimed |
| US-20090304799-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009132342-A1 | NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009132343-A1 | NANOEMULSIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009131995-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| US-20080050842-A1 | METHOD OF VISUALIZATION AND QUANITIFICATION OF BIOPOLYMER MOLECULES IMMOBILIZED ON SOLID SUPPORT | GOLOVLEV VALERI V | 2008-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102479-A1 | METHOD FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES | CD47, RPS4X, INCENP | NR1H4 3666/4885GPBAR1 4303/4885ABCB11 3046/4885 |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | NR1H4 2968/4885GPBAR1 3949/4885ABCB11 1334/4885 |
| US-20100075914-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | NR1H4 2563/4885GPBAR1 3639/4885ABCB11 3863/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | NR1H4 2915/4885GPBAR1 4246/4885ABCB11 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.